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High-intensity exercise improves pulmonary function 
and exercise tolerance in a patient with TSC-LAM
Abstract
Introduction: While exercise has been shown to improve respiratory symptoms, exercise tolerance, and bone mineral density 
in many populations, no supervised exercise training interventions have been undertaken in patients with lymphangioleiomyo-
matosis (LAM).
Material and methods: One patient with TSC-LAM (tuberous sclerosis complex lymphangioleiomyomatosis) participated in two 
weekly sessions (50–60 min) of supervised aerobic exercise at 80–85% heart rate max for one year. Treadmill ergometry (VO2peak), 
spirometry (FEV1, FVC, FEV1/FVC, peak flow), and bone mineral density testing were performed prior to every 3 months.
Results: After one year of supervised aerobic exercise training we saw dramatic increases in the patient’s VO2max (20%), FEV1 
(9.5%), FEV1/FVC (9.1%) and peak flow (47%). 
Conclusions: The results from this study indicate that supervised exercise training can improve exercise tolerance and pulmonary 
function in a patient with lymphangioleiomyomatosis. Further research is needed, including longitudinal studies with larger sample 
sizes, to determine long-term effects and consistency of these findings. Aerobic exercise may offer a viable alternative or com-
pliment to pharmacological interventions in the treatment of lymphangioleiomyomatosis. We show that high-intensity exercise 
training can markedly and safely improve pulmonary function in a patient with TSC-LAM. While we did not record quality of life 
or mood states, our patient did report improved self-confidence as well as enhanced mood.
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Introduction
Approval was obtained from the Committee 
for Protection of Human Subjects at the Universi-
ty of Houston and the Institutional Review Board 
at the University of Texas Health Science Center 
(UTHSC) and at the University of Central Arkan-
sas. Written informed consent was obtained from 
our patient prior to data collection. A 29-year-old 
female with tuberous sclerosis complex lymphan-
gioleiomyomatosis (TSC-LAM; TSC diagnosed in 
1988, age 5; LAM in 2004, age 21) with a history 
of related complications (more than twenty pneu-
mothoraces, resulting in bilateral pleurodesis 
and pleurectomy; angiomyolipomas resulting in 
partial nephrecotmy) was referred from the UTH-
SC LAM Clinic by her LAM specialist. Her last 
pneumothorax was approximately five years prior 
to her inclusion in this trial (age 23), when she re-
ceived her bilateral pleurectomy/pleurodesis. The 
psychological state of the patient was motivated 
but she was lacking in confidence in her ability 
to perform even moderate exercise (e.g., more 
than walking at a slow pace on a treadmill for 
more than a few minutes). The patient was taking 
sirolimus for 3 years, switching to afinitor 4 years 
ago due to attenuation (sirolimus benefits were 
plateauing) of sirolimus on disease. The patient 
did not have any brain lesions, nor had she ever 
experienced any episodes of epilepsy. 
Material and methods
Pulmonary function tests (PFTs), a graded ex-
ercise test (GXT), and bone mineral density (BMD) 
were assessed prior to beginning exercise training 
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(pre) and every three months. Twice weekly the 
patient reported for supervised exercise training 
(60 min/session), consisting of high-intensity aer-
obic (primarily treadmill/track running/sprinting) 
and resistance training. Patient performed a GXT 
to volitional fatigue to determine VO2max using 
a Woodway Desmo treadmill (Waukesha, WI, USA) 
and a Quark CPET metabolic cart (Cosmed, Rome, 
Italy). PFTs were assessed using the Quark CPET 
metabolic cart. A Discovery QDR-4500 for Win-
dows (Hologic, Inc., Bedford, MA, USA) dual X-ray 
absorptiometry (DXA) scanner was used to assess 
BMD. Tests were completed in room air without 
bronchodilator. PFTs prior to baseline (-60 months, 
-18 months) were taken from patient records.
Our patient demonstrated marked improve-
ments in VO2max (Figure 1A), FEV1 (forced expira-
tory volume in 1 second) and FEV1/FVC (forced 
vital capacity) % (Figure 1B and 1C), and peak 
flow (Figure 1D). Whole body and spine BMD 
also slightly improved or remained high despite 
already-high levels (Table 1). Forced vital capacity 
remained steady from baseline (Table 1). Patient 
maintained bodyweight (61.4–64 kg) and body 
fat (21.9–27.2%) pre to post. Peak flow improved 
by 47%; relative and absolute VO2max improved 
by 20% and 23.4%, respectively. We do not have 
pulmonary function tests for the patient prior to 
her initial use of either sirolimus or following 
cessation of the drug. The baseline (-60 months) 
were taken approximately one year prior to the 
patient switching to Afinitor and the -18 months 
measures were the most recent PFT measures 
taken prior to her being seen in our laboratory. 
Discussion
Lymphangioleiomyomatosis is a rare, multi-
system disease affecting women of child-bearing 
age almost exclusively and can occur sporadically 
or as a manifestation of TSC-LAM [1]; indeed, 
LAM occurs in at least 40% of women with TSC 
[2]. Severe cases can lead to respiratory failure. 
Spontaneous pneumothoraces are common and 
Figure 1. Oxygen uptake (VO2max) and pulmonary function tests
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are often the primary event leading to diagnosis 
and in most cases clinical events existed prior to 
diagnosis with one-third of patients exhibiting 
normal spirometry and obstruction evident in 
57% of patients [3]. Despite great advances in 
diagnosis and patient management over the past 
two decades, treatment options are limited. As 
such, lifestyle choices and treatment options 
should be made as early as possible [2].
Sirolimus targets the mammalian target of 
rapamycin (mTOR) pathway and has been tre-
mendously effective in improving pulmonary 
function in the majority of patients with LAM 
[4]. However, once treatment is stopped im-
provement disappears, and sirolimus appears to 
have a much greater effect in reducing extrapul-
monary masses rather than pulmonary cysts [5]. 
Further, angiomyolipomas increase once therapy 
is stopped [6] and LAM is recurrent following 
lung transplant [7]. FEV1 is considered the most 
clinically-relevant marker in determining disease 
severity [8]; patients with FEV1 < 30% are often 
placed on transplant list. Improved FEV1 could 
translate into reduced disease severity, potentially 
increasing time-to-transplant. A 100 mL increase 
in FEV1 has been shown to be clinically important 
in COPD as this can be perceived by patients [9], 
and Westwood determined that a 100 mL increase 
in FEV1 was associated with improved health 
status [10]. Our patient exhibited an elevated and 
sustained FEV1 of 230 mL (10% increase, Table 1) 
beginning at 6 months. Exercise tolerance may be 
as clinically relevant as FEV1 [11], as individuals 
able to perform even moderate physical activity 
would likely have a much-improved quality of 
life. Here we show an improvement in pulmonary 
function and exercise tolerance (VO2). 
Using exercise to treat women with LAM or 
TSC-LAM is novel. To date, only one study has 
examined the role of exercise in women with LAM 
[12]. While that study used exercise, only mod-
erate exercise training was prescribed, and only 
12 weeks (3 months) of exercise training was un-
dertaken. Here we report on increased pulmonary 
function in a 29-year-old female with TSC-LAM 
following one year of intense exercise training. 
FEV1 and peak flow improved at three and six 
months, with large increases after nine and twelve 
months (Figure 1A, D). VO2 improved steadily, 
peaking at 6 months and remaining elevated. No 
decline in pulmonary function was seen after one 
year, unlike sirolimus [4]. These remarkable im-
provements demonstrate the potential of exercise 
to improve lung function in women with LAM. 
Increases were much more dramatic 9–12 months 
than 3–6 months after beginning the exercise inter-
vention, with levels continuing to rise at one year. 
Our patient is continuing to exercise to determine 
if these measures remain elevated past one year. 
This is the first study in the literature that demon-
strates the use of high-intensity exercise to treat 
LAM. This presents the possibility of extending 
time-to-transplant with minimal, non-invasive 
intervention. As VO2 is correlated with disease 
severity [11], improved VO2 translates clinically 
and physiologically for patients with LAM.
We are presently preparing a manuscript 
examining a larger (n = 8) group of LAM (seven 
sporadic LAM and one TSC-LAM) patients exam-
ining the positive benefits of exercise training on 
pulmonary function and bone mineral density at 
3, 6, 9, and 12 month intervals. While the results 
of that study demonstrated marked improve-
ments, this patient exhibited even greater results 
following high-intensity (as opposed to moderate- 
to moderately-high intensity) exercise training. 
Although quite deconditioned, the patient in 
this present study was remarkably healthy aside 
Table 1. Pulmonary function tests, VO2max, and bone mineral density 
Measure -60 months -18 months Pre 3 months 6 months 9 months 12 months
FEV1/FVC [%] 84.0 75.0 66.3 66.4 68.4 70.9 73.4
FVC [L] 4.33 3.71 3.82 3.88 3.80 3.97 3.82
FEV1 [L] 3.04 2.35 2.53 2.56 2.57 2.75 2.76
Peak flow [L] 5.32 5.26 3.71 4.85 4.36 5.4 5.45
VO2max [mL/kg/min] 29.43 34.66 37.02 35.23 35.34
VO2 [L/min] 1833 2160 2351 2254 2262
DXA, whole body (g/cm2) 1.3 1.277 1.31 1.275 1.308
DXA, lumbar spine (g/cm2) 1.326 1.346 1.31 1.337 1.299
FEV1 — forced expiratory volume in 1 second; FVC — forced vital capacity
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from the pulmonary issues associated with TSC-
LAM and was thus able to eventually participate 
in high-intensity exercise. Indeed, the patient’s 
pulmonary function (FEV1, peak flow) showed 
the greatest improvements after she had been 
training for more than six months, indicating that 
the patient needed to be conditioned before she 
could be trained using high-intensity exercise 
training. LAM and TSC-LAM patients undergo-
ing pulmonary rehabilitation should consider 
longer-term training programs that will allow 
them to become conditioned to a level such that 
they can participate in rigorous (high-intensity) 
exercise programs to improve their gains made 
during exercise training. 
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